No Data
No Data
Pfizer Hemophilia B Gene Therapy Durveqtix Wins EC Authorization
Pfizer Gets EC's Conditional Authorization For Durveqtix Genetherapy In Hemophilia B
Pfizer's Hemophilia B Treatment Gets Conditional Marketing Authorization in Europe
Pfizer Gets European Commission Marketing Approval for Durveqtix
Express News | European Commission Approves Pfizer’s Durveqtix® (Fidanacogene Elaparvovec), a One-Time Gene Therapy for Adults With Hemophilia B
Pfizer's Options: A Look at What the Big Money Is Thinking
No Data